Genedx Holdings CORP Form 4 insider transactions

Emily M. Leproust, a director of GeneDx Holdings Corp., acquired 12,924 restricted stock units (RSUs) on June 26, 2024, which will vest on the earlier of the next annual meeting or the first anniversary of the grant date.

Richard C. Pfenniger Jr., a director of GeneDx Holdings Corp., acquired 12,924 restricted stock units (RSUs) on June 26, 2024, representing a contingent right to receive shares of Class A Common Stock.

Director Ryan Jason acquired 12,924 restricted stock units (RSUs) of GeneDx Holdings Corp. on June 26, 2024, which will vest within the next year.

Director Eli Casdin acquired 12,924 restricted stock units (RSUs) of GeneDx Holdings Corp. on June 26, 2024, which will vest on the earlier of the next annual meeting or the first anniversary of the grant date.

Director Keith A. Meister acquired 12,924 restricted stock units (RSUs) of GeneDx Holdings Corp. on June 26, 2024, which will vest within the next year.

Eli Casdin, a director and 10% owner of GeneDx Holdings Corp., reports changes in beneficial ownership of Class A Common Stock and Restricted Stock Units (RSUs) following the vesting of RSUs.

Emily M. Leproust, a director at GeneDx Holdings Corp., reported the acquisition and disposal of Class A Common Stock and Restricted Stock Units on June 20, 2024.

Director Richard C. Pfenniger Jr. of GeneDx Holdings Corp. reports the disposition of 5,828 shares of Class A Common Stock to cover restricted stock units.

Director Joshua Ruch reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units in GeneDx Holdings Corp.

Director Keith Meister reports a transaction involving Class A Common Stock and Restricted Stock Units of GeneDx Holdings Corp.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

GeneDx Holdings Corp.'s CEO, Katherine Stueland, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Casdin Capital and related entities have increased their holdings in GeneDx Holdings Corp. through a series of open market purchases of Class A Common Stock.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Casdin Capital, a significant shareholder in GeneDx Holdings Corp., has reported the acquisition of 40,000 shares of Class A Common Stock at an average price of $21.0651.

Casdin Capital and related entities have increased their holdings in GeneDx Holdings Corp. through a series of open market purchases, as detailed in a recent SEC Form 4 filing.

Casdin Capital, a significant shareholder in GeneDx Holdings Corp. (WGS), reported the acquisition of 50,000 shares of Class A Common Stock at a price of $23.3059 per share on May 13, 2024.

Director Richard C. Pfenniger Jr. acquired 918 shares of GeneDx Holdings Corp. Class A Common Stock on May 2, 2024, through the vesting of restricted stock units.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposition of Class A Common Stock related to the vesting and settlement of Restricted Stock Units (RSUs).

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Kareem Saad, Chief Transformation Officer of GeneDx Holdings Corp., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

Kevin Feeley, CFO of GeneDx Holdings Corp., sold 931 shares of Class A Common Stock on March 12, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

GeneDx Holdings CEO Katherine Stueland sold 2,618 shares of Class A Common Stock on March 12, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Kareem Saad, Chief Transformation Officer of GeneDx Holdings Corp., sold 897 shares of Class A Common Stock to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition of 2,462 Class A Common Stock units through the vesting of restricted stock units on March 9, 2024.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition of 6,547 shares of Class A Common Stock and corresponding disposal of restricted stock units on March 9, 2024.